Showing 2,621 - 2,640 results of 10,572 for search '"Tumor"', query time: 0.08s Refine Results
  1. 2621
  2. 2622
  3. 2623
  4. 2624
  5. 2625
  6. 2626

    Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells by Valentin P. Shichkin, Roman M. Moriev

    Published 2014-01-01
    “…Previously, the mouse A20 B-cell lymphoma engineered to express hemagglutinin (HA) antigen (A20HA) was used as a systemic tumor model. In this work, we used the A20HA cells as a brain tumor. …”
    Get full text
    Article
  7. 2627

    Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cm by Jorge Raul Vazquez-Urrutia, Junjia Zhu, Shinkichi Takamori, Max Greenberg, Priyanka Bhatia, Takefumi Komiya

    Published 2025-01-01
    “…Abstract Background The role of adjuvant chemotherapy in early-stage small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) remains unclear, particularly for small tumors. This study assesses the survival benefits of adjuvant chemotherapy after surgical resection with a novel focus on tumors less than 1 cm. …”
    Get full text
    Article
  8. 2628

    Rare Case of a Young Male Presented with Abdominal Pain, Solid Colon Tumors, and Eosinophilia, Followed by Tremendous Thromboembolic Complications and Eventually Diagnosed with Idiopathic Hypereosinophilic Syndrome by Tomasz Zemleduch, Anna Czapla, Piotr Kimla, Bartosz Kudliński

    Published 2022-01-01
    “…We document a case of a young male presented with persistent abdominal pain with two eosinophilic colon tumors. The patient suffered from phlegmasia cerulea dolens and portal vein thrombosis, followed by pulmonary embolism and overt disseminated intravascular coagulation (DIC). …”
    Get full text
    Article
  9. 2629
  10. 2630
  11. 2631

    Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor by Weiting Liao, Ge Gao, Xia He, Pei Shu, Qizhi Ma, Benxia Zhang, Diyuan Qin, Yongsheng Wang

    Published 2023-08-01
    “…Backgrounds Chimeric antigen receptor (CAR)-modified T cells (CAR-T) are limited in solid tumors due to the hostile tumor microenvironment (TME). …”
    Get full text
    Article
  12. 2632
  13. 2633

    CpG Oligodeoxynucleotides Enhance the Efficacy of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes by Modifying the Th1 Polarization and Local Infiltration of Th17 Cells by Lin Xu, Chunhong Wang, Zhenke Wen, Ya Zhou, Zhongmin Liu, Yongjie Liang, Zengguang Xu, Tao Ren

    Published 2010-01-01
    “…Adoptive cell transfer immunotherapy using tumor infiltrating lymphocytes (TILs) was an important therapeutic strategy against tumors. …”
    Get full text
    Article
  14. 2634
  15. 2635
  16. 2636
  17. 2637

    First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

    Published 2024-07-01
    “…Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.Trial design The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. …”
    Get full text
    Article
  18. 2638
  19. 2639

    Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy by Shi Chen, Li-Ying Ou-Yang, Run-Cong Nie, Yuan-Fang Li, Jun Xiang, Zhi-Wei Zhou, Ying-Bo Chen, Jun-Sheng Peng

    Published 2017-01-01
    “…To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. …”
    Get full text
    Article
  20. 2640

    The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction by Junjie Hang, Junjie Huang, Siyuan Zhou, Lixia Wu, Yingwei Zhu, Lina Zhu, Hanyu Zhou, Kequn Xu, Hua Jiang, Xuguang Yang

    Published 2019-03-01
    “…Abstract Naïve and memory T cells play a pivotal role in solid tumor pathogenesis but their role in pancreatic cancer progression remains elusive. …”
    Get full text
    Article